肝癌疫苗的表位預測

肝癌是亞洲國家常見的癌症之一。當醫師診斷出病人罹患肝癌時，經常都已經是肝癌晚期，導致肝癌的治療無法真正的治癒。肝癌的治療方法有很多種，手術治療、化學療法和放射療法等，但這些方法都有各自的限制性，無法真正的消除腫瘤細胞，因此希望研發疫苗來改善肝癌無法治癒的情況。癌症疫苗中若存在著有效的细胞毒性T 淋巴细胞（CTL）表位（epitope），那在免疫系統中這些CTL表位將可以阻止腫瘤的成長。因此我們嘗試在CT 抗原中尋找肝癌疫苗可能的有效表位。參考肝癌文獻，進行十六個CT 抗原表位預測。肝癌疫苗中的有效表位可以誘發人體形成CTL 消滅腫瘤。利用兩個線上表位預測工具NetCTL 與MAPPP 伺服器進行預測，兩個伺服器共同得到的相同最佳表位是有效表位。文獻中十六個表達在肝癌的CT 抗原，包括SSX1、SSX2、SSX4、SSX5、NY-ESO-1 、SCP-1 、HCA587 、XAGE-1b 、OY-TES-1 、CAGE 、HCA661 、FATE/BJ-HCC-2、TPTE/BJ-HCC-5、KM-HN-1、ZNF165 和TSPY，得到四個最佳表位RLQGIFPKI、YLMPGFIHL、SLTEANEEL 和LLDDIMAEV，它們是肝癌多價疫苗的最佳候選目標，表位的位置在NetCTL 和MAPPP 伺服器是一致，而這些表位來自SSX5、CAGE、HCA661 和TSPY 蛋白，在肝癌均有高度的表達。表位預測的資料可以提供相關資訊給未來的肝癌疫苗研究者，減少表位實驗研究的盲目性。

關鍵字

抗原；表位；疫苗；肝癌

並列摘要

Liver cancer is one of the most common cancers in some Asia countries. It becomes fatal very fast after diagnosis because it is typically detected at late stages. Therefore most of therapies for liver cancer can not prevent deaths, but postpone them. Vaccination is one of hopeful alternative treatments. Cancer vaccination is to stimulate the immune system to recognize tumors and attack them. Consequently, it may block tumour grow if the vaccine contains effective epitopes for the immune system to recognize tumors. Therefore, we try to find some effective epitopes for preparing liver cancer vaccines. We survey sixteen CT antigens which have been reported to be expressed in liver cancer cells. We computationally test them to obtain the most possible epitopes for cytolytic T lymphocyte (CTL) mediated immune response. Two on-line CTL epitope prediction tools are used: NetCTL and MAPPP. We then collect the set of epitopes if both algorithms come out with the same predictions. We investigated sixteen CT antigens for liver cancer. We got four epitopes RLQGIFPKI, YLMPGFIHL, SLTEANEEL and LLDDIMAEV. The results mean that these epitopes are consistently pointed out by both NetCTL and MAPPP and could be used to design a potential multi-epitope vaccine for liver cancer. There epitopes come from SSX5, CAGE, HCA661 and TSPY protein sequences which highly expressed in liver cancer cells.

並列關鍵字

antigen ； epitope ； vaccine ； liver cancer

參考文獻

1. 行政院衛生署，歷年癌症死亡原因，行政院衛生署，(2007)。

2. 蕭雅莉，肝癌患者接受立體定位放射線治療期間疲倦改變及相關因素之探討，台北醫學院護理學研究所，(2002)。

6. Sahin U, Türeci O, Pfreundschuh M., Serological identification of human tumor antigens, Curr Opin Immunol, 9(5):709-16, (1997).

10. Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, Pang XW, Zhang Y,Chen WF., TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma, Br J Cancer, 93(4):458-63, (2005).

11. Yang XA, Dong XY, Qiao H, Wang YD, Peng JR, Li Y, Pang XW, Tian C, Chen WF., Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues, Lab Invest, 85(2):205-13, (2005).

國際替代計量

肝癌疫苗的表位預測

未授權

主題瀏覽